Open Access Open Access  Restricted Access Subscription or Fee Access

Tolerability and efficacy of tapentadol extended release in elderly patients ≥75 years of age with chronic osteoarthritis knee or low back pain

David M. Biondi, DO, Jim Xiang, PhD, Mila Etropolski, MD, Bruce Moskovitz, MD

Abstract


Objective: Management of chronic pain in elderly adult patients is often complicated by analgesic medication–related side effects. This post hoc analysis of pooled data evaluated the tolerability and analgesic efficacy of tapentadol extended release (ER) compared with oxycodone controlled release (CR) in elderly adult patients (75 years of age) with moderate to severe, chronic osteoarthritis knee or low back pain.

Methods: Data were pooled from three similarly designed, randomized, double-blind, placebo- and active-controlled, phase 3 studies of tapentadol ER for moderate to severe, chronic osteoarthritis knee (NCT00421928, NCT00486811) or low back (NCT00449176) pain, and data for patients 75 years of age were evaluated. Each study consisted of a 3-week titration and 12-week maintenance period. Patients received placebo, tapentadol ER (100-250 mg bid), or oxycodone HCl CR (20-50 mg bid). Tolerability was evaluated using adverse event reporting. Efficacy was evaluated using pain intensity ratings (11-point numerical rating scale).

Results: For patients 75 years of age (n = 210), incidences of gastrointestinal treatment-emergent adverse events (TEAEs) overall and TEAEs of vomiting and the composite of nausea and/or vomiting were significantly lower in the tapentadol ER group compared with the oxycodone CR group (all p 0.0206). Tapentadol ER treatment was associated with significant reductions in pain intensity from baseline to week 15 compared with placebo (p = 0.0075); differences between the oxycodone CR and placebo groups failed to reach statistical significance (p = 0.1195), likely related to a higher treatment discontinuation rate in the oxycodone CR group. No significant differences were observed between the tapentadol ER and oxycodone CR groups in the change in pain intensity from baseline to week 15 (p = 0.2135).

Conclusions: In elderly adult patients 75 years of age with moderate to severe, chronic osteoarthritis knee or low back pain, tapentadol ER (100-250 mg bid) provided significant pain relief compared with placebo and had a better overall gastrointestinal tolerability profile than oxycodone CR.


Keywords


tapentadol, chronic pain, elderly

Full Text:

PDF

References


Ferrell BA: Pain evaluation and management in the nursing home. Ann Intern Med. 1995; 123(9): 681-687.

Barkin RL, Barkin SJ, Barkin DS: Perception, assessment, treatment, and management of pain in the elderly. Clin Geriatr Med. 2005; 21(3): 465-490, v.

Cavalieri TA: Pain management in the elderly. J Am Osteopath Assoc. 2002; 102(9): 481-485.

Malanga G, Paster Z: Update on managing chronic pain in the elderly. J Fam Pract. 2007; 56(12 suppl new): S11-S16.

Avouac J, Gossec L, Dougados M: Efficacy and safety of opioids for osteoarthritis: A meta-analysis of randomized controlled trials. Osteoarthr Cartil. 2007; 15(8): 957-965.

Hale M, Tudor IC, Khanna S, et al.: Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: Results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther. 2007; 29(5): 874-888.

Matsumoto AK, Babul N, Ahdieh H: Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: Results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med. 2005; 6(5): 357-366.

Hale ME, Fleischmann R, Salzman R, et al.: Efficacy and safety of controlled-release versus immediate-release oxycodone: Randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain. 1999; 15(3): 179-183.

Hale ME, Ahdieh H, Ma T, et al.: Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: A 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007; 8(2): 175-184.

Rauck RL, Bookbinder SA, Bunker TR, et al.: A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: Improved physical functioning in the ACTION trial. J Opioid Manag. 2007; 3(1): 35-43.

American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons: Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009; 57(8): 1331-1346.

Pergolizzi J, Boger RH, Budd K, et al.: Opioids and the management of chronic severe pain in the elderly: Consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008; 8(4): 287-313.

Tzschentke TM, Christoph T, Kögel B, et al.: (−)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): A novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007; 323(1): 265-276.

Tzschentke TM, De Vry J, Terlinden R, et al.: Tapentadol hydrochloride. Analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitor. Drugs Future. 2006; 31(12): 1053-1061.

Nucynta® ER (tapentadol) extended-release oral tablets C-II [package insert]. Raritan, NJ: Janssen Pharmaceuticals, Inc., 2011.

Afilalo M, Etropolski MS, Kuperwasser B, et al.: Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010; 30(8): 489-505.

Buynak R, Shapiro DY, Okamoto A, et al.: Efficacy and safety of tapentadol extended release for the management of chronic low back pain: Results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother. 2010; 11(11): 1787-1804.

Schwartz S, Etropolski M, Shapiro DY, et al.: Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011; 27(1): 151-162.

Wild JE, Grond S, Kuperwasser B, et al.: Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010; 10(5): 416-427.

Lange B, Kuperwasser B, Okamoto A, et al.: Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010; 27(6): 381-399.

OxyContin® (oxycodone hydrochloride controlled-release) tablets [package insert]. Stamford, CT: Purdue Pharma L.P., 2010.

Papaleontiou M, Henderson CR Jr, Turner BJ, et al.: Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: A systematic review and meta-analysis. J Am Geriatr Soc. 2010; 58(7): 1353-1369.

Wilder-Smith OH: Opioid use in the elderly. Eur J Pain. 2005; 9(2): 137-140.

Buckeridge D, Huang A, Hanley J, et al.: Risk of injury associated with opioid use in older adults. J Am Geriatr Soc. 2010; 58(9): 1664-1670.

Miller M, Sturmer T, Azrael D, et al.: Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc. 2011; 59(3): 430-438.

Solomon DH, Rassen JA, Glynn RJ, et al.: The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010; 170(22): 1968-1976.

Solomon DH, Rassen JA, Glynn RJ, et al.: The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010; 170(22): 1979-1986.




DOI: http://dx.doi.org/10.5055/jom.2015.0289

Refbacks

  • There are currently no refbacks.
This site uses cookies to maintain session information critical to the user's experience and environment on this system. Click "Accept Cookies" to continue.
For more details please visit our privacy statement at: Privacy & GDPR